OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

I agree - have a good weekend and stay lucky.

FINANCIAL TIMES today


Oxford Biomedica
Published: October 9 2004 03:00 | Last updated: October 9 2004 03:00

Shares in Oxford Biomedica rose 21 per cent to 20p after Panmure Gordon initiated coverage of the biotech company with a "buy" recommendation and a target price of 50p. The broker said: "We like Oxford Biomedica because uniquely in the UK biotech sector it has a large number of products at a relatively late stage of R&D. This provides a security net against 'all the eggs in one basket' slip-ups". The company is working on two cancer drugs and several neurotherapy treatments. Panmure expects Oxford Biomedica to sign at least one and up to three partnership deals next year.

Great post Janus. Surely if it signs 3 partnership deals next year 50p will be the very least we could hope for.

UP again so far today.

First obstacle is to get through the 21p barrier - followed by some good news - I am off for a couple of weeks and will be watching daily (from a sun bed with an expensive newspaper)how you all get on in my absence

Enjoy your basting Oakaooles142!

12/10/04 10:37 Director Shareholding RNS


Oxford Biomedica PLC
12 October 2004


Oxford BioMedica plc ('the Company')

Directors' Interest in Options over 1p Ordinary Shares

12 October 2004

The Company announced that today it has granted additional share options to
certain Directors, under the Oxford BioMedica 1996 (No.1) Share Option Scheme.
The exercise price for each of the options is 20.5 pence per share. There was no
payment in respect of the grant of these options. The new options may be
exercised between 12 October 2007 and 12 October 2011, but only if at the time
of exercise, or for at least 12 months in the three years before exercise, the
percentage increase in Oxford BioMedica's Total Shareholder Return exceeds the
percentage increase in the FTSE TechMark Mediscience index since the date of
grant of the option. The new options granted to directors are: Professor Alan
Kingsman 190,000 options, Professor Susan Kingsman 155,000 options, Peter Nolan
140,000 options and Andrew Wood 175,000 options.

Following the grant of these options, the interests of these directors in
options over 1p ordinary shares of the Company are: Professor Alan Kingsman
370,000 options, Professor Susan Kingsman 305,000 options, Peter Nolan 1,111,229
options and Andrew Wood 1,505,036 options.

Andrew Wood
Company Secretary, Oxford BioMedica plc
Tel. 01865 783000
12 October 2004

Small rise yesterday, looks like more coming today.

so its maintained 21p for a couple of days, where's the good news then ???

Cancer News Article



New Vaccine for Treatment of Colorectal Cancer Shows Promise in Phase II Trial
The results of a recent phase II study conducted in Europe indicate that TroVax is promising for the treatment of stage IV colorectal cancer.

Colorectal cancer is the second leading cause of cancer related deaths in the United States. Colorectal cancer is a malignancy that involves both the large intestines (colon) and a distal portion of the colon known as the rectum. Current treatment options for colorectal cancer include surgery, radiation and chemotherapy.

Another type of cancer treatment is biologic therapy, which uses the bodys own immune system to fight cancer. The immune system is the bodys natural defense against foreign substances and abnormal growth. It is a complex system that relies on many different substances and steps to effectively defend the body against foreign invaders, such as viruses and bacteria, and abnormal growth, such as cancer. Biological therapies are substances that can interfere in any number of these steps to help the immune system recognize and kill cancer cells. Biological therapies are produced in a laboratory and may be replications of naturally occurring substances or synthetic substances.

TroVax is a new drug developed to stimulate the patients immune system to mount an antibody response against the 5T4 antigen associated with colorectal cancer. The trial conducted in England is not yet complete; however, interim analysis has shown that TroVax is safe when given in addition to standard chemotherapy and patients are able to mount an immune response to the antigen. TroVax would be the first type of immunotherapy developed for the treatment of colon cancer.

The recently published report is based on 13 patients who received 4 TroVax injections and at least 8 cycles of chemotherapy. Of these 13 patients, 11 (85%) mounted antibody responses to the 5T4 antigen. Further analysis will be published in 2005 when all patients will have completed 6 doses of TroVax and 12 cycles of chemotherapy.

Two additional trials are also being analyzed comparing TroVax given with fluorouracil, leucovorin and irinotecan chemotherapy (IFL), or TroVax given with fluorouracil, leucovorin and oxaliplatin chemotherapy. (FOLFOX). At this time, 9 of the10 patients who received IFL and TroVax have mounted an immune response to the 5T4 antigen. In the group receiving FOLFOX with TroVax, only 3 of the 17 patients are currently ready for interim analysis and of these, 2 have mounted an anti-tumor response (67%).

Further trials of TroVax are ongoing and researchers are confident that TroVax will have a role in the treatment of colorectal cancer.

Reference: Pharmalive.com. Oxford Biomedica Announces Positive Interim Phase II Results with Trovax in Colorectal Cancer. http://www.pharmalive.com.

1998- 2004 CancerConsultants.com All Rights Reserved.

These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. All readers should verify all information and data before administering any drug, therapy or treatment discussed herein. Neither the editors nor the publisher accepts any responsibility for the accuracy of the information or consequences from the use or misuse of the information contained herein.

Thanks The Gull,

Where did you get that from?

What was the internet address?

Apple

Typed TroVax into google search, below is one of the links that came up.

I just copy pasted the article - not sure when it was written?

imo - seems the industry sentiment is quite positive.

http://patient.cancerconsultants.com/news.aspx?id=31375

AICR.

Regards

Gull

Thanks

Sold half,

It looks like we'll drift down again until the next news.

BIOMEDICA ANNOUNCES POSITIVE INTERIM PHASE II RESULTS WITH TROVAX IN COLORECTAL CANCER

Oxford BioMedica (LSE: OXB) announced that the primary endpoints have been achieved at the interim stage of two Phase II trials in patients with Stage IV colorectal cancer receiving TroVax alongside chemotherapy. TroVax is the Companys novel cancer immunotherapy product against the tumour associated antigen 5T4. The primary endpoints are safety and demonstrable anti-tumour immune responses against the 5T4 tumour antigen.
<>The results from an interim analysis of both trials, initiated in 2003, showed that the combination of TroVax and standard of care chemotherapy is safe and that patients mount specific immune responses to the 5T4 antigen. Full recruitment is imminent across both trials with 36 of 37 projected patients enrolled. The objective is to have ten evaluable patients in each setting. The interim results are based on 13 patients in total, who have reached an interim analysis point defined as four TroVax immunisations and more than eight cycles of chemotherapy. There have been no serious adverse events associated with TroVax treatment and the product was well tolerated. 11 of the 13 patients (85%) mounted antibody and/or cellular immune responses to the 5T4 tumour antigen following four immunisations with TroVax. <>

The Company expects to report full safety and immunological data in mid-2005 when all patients will have received 12 cycles of chemotherapy and 6 doses of TroVax. At this time, tumour response rates will also be determined. <>

<>Commenting on the Phase II results, Prof. Alan Kingsman, Chief Executive of Oxford BioMedica, said, /We are very pleased with the progress of our first Phase II trials with TroVax. The high number of anti-5T4 responses at this interim stage suggests that patients are able to mount an anti-tumour immune response even in the context of chemotherapy treatment. In our earlier Phase I/II trials, it was clear that anti-5T4 immune responses correlated with improved patient survival. We now feel confident that TroVax has a role to play in the treatment of colorectal cancer.

Up again today!

Oh well,

sold half at the wrong moment.

hlyeo98, that RNS you posted was from Sep 1st, it is not new.

Patent issued Oct 5th

Nice to know that the paperwork is progressing since it was filed in 2001.

Thanks for that Apple - post 184 - another step forward.

Some old news

Link to Info Source

They are a bit late publishing this but there you go.

Oxford Biomedica Signs License Agreement with Massachusetts General Hospital & Dana-Farber Cancer Institute
Publish Date : 10/20/2004 10:03:00 AM Source : Onlypunjab.com Team


Oxford BioMedica (LSE: OXB), the cancer and neurobiological gene therapy company, announced today that it has signed an agreement with Massachusetts General Hospital, Boston University and Dana-Farber Cancer Institute extending the field of Oxford BioMedicas exclusive access to the family of cytochrome P450 enzymes in cancer gene therapy. The P450 enzyme is used in Oxford BioMedicas novel cancer gene therapy product, MetXia. The extension of the license covers the development of MetXia as a treatment for pancreatic cancer.

Under a separate agreement, Massachusetts General Hospital, Boston University and Dana-Farber Cancer Institute have subscribed for a total of 352,887 ordinary shares of 1p each at 15.78 pence per share.

The P450 enzyme is naturally expressed in the liver and activates the chemotherapeutic drug cyclophosphamide. By delivering a specific P450 gene, MetXia promotes activation of cyclophosphamide directly in the tumour and thereby enhances its potency as an anti-tumour treatment. Oxford BioMedica licensed the rights to the P450 enzyme for cancer gene therapy from Massachusetts General Hospital, Boston University and Dana-Farber Cancer Institute in 1997 and extended the agreement previously in 2000.

Oxford BioMedica has demonstrated proof of concept with MetXia in two Phase I/II trials in patients with accessible tumours, primarily in breast cancer. In April 2004, the Company reported that recruitment had started in a Phase I trial, rolling into a Phase II trial in patients with pancreatic cancer. The safety stage of this trial is on-track to complete by the end of the year.

Could help attract investors from further affield.
But more than likely just keeping the locals informed on the progress being made in this industry.